Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 244 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pneumovax Clear all
Completed Phase 1 Interventional

Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma

NCT00834665
View directory record Official record
Conditions
Multiple Myeloma
Interventions
hTERT vaccine, GM-CSF, PCV, T cell infusion, GM-CSF, PCV, T cell infusion
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Persistent Readiness Through Early Prediction Immunization Study

NCT05346302
View directory record Official record
Conditions
Inflammatory Response
Interventions
Pneumovax 23, Typhim VI, Saline
Drug · Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 40 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants

NCT00444457
View directory record Official record
Conditions
Vaccines, Pneumococcal
Interventions
13-valent Pneumococcal Conjugate Vaccine, 7vPnC
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
1,712 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
78
States / cities
Benton, Arkansas • Conway, Arkansas • Fayetteville, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 22, 2026, 5:11 AM EDT
Completed No phase listed Observational Results available

Impact of Prevnar 13 on Ear Infections in Children

NCT01272999
View directory record Official record
Conditions
Acute Otitis Media, Mastoiditis
Interventions
No intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 22, 2026, 5:11 AM EDT
Completed No phase listed Observational

Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia

NCT05007860
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

NCT00505063
View directory record Official record
Conditions
Childhood Cancer, Multiple Diseases
Interventions
Immunization Schedule patients <7 years., Immunization Schedule patients > or = to 7 years and <11 years of age, Immunization Schedule patients > or = to 11 years of age
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

NCT00743652
View directory record Official record
Conditions
Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Interventions
13-valent Pneumococcal Conjugate Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 5 Years
Enrollment
373 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
21
States / cities
Akiak, Alaska • Bethel, Alaska • Chefornak, Alaska + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

NCT01702428
View directory record Official record
Conditions
Rubella, Measles, Mumps
Interventions
Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
5,016 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
62
States / cities
Dothan, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

NCT03692871
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
22
States / cities
Downey, California • Huntington Beach, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Early Phase 1 Interventional

Multi-peptide Vaccine With Basilixumab for Breast Cancer

NCT01660529
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
hTERT
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional

Maternal Immunization To Prevent Infant Otitis Media

NCT00617682
View directory record Official record
Conditions
Otitis Media
Interventions
PNCRM9, Placebo comparator
Biological
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years and older · Female only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Bloomington, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 18, 2008 · Synced Oct 22, 2026, 5:11 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

NCT07348692
View directory record Official record
Conditions
Pneumococcal Immunization, Healthy Volunteers
Interventions
PCV21 vaccine, 20vPCV licensed vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
14
States / cities
Fayetteville, Arkansas • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

NCT06698198
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
Pneumococcal Conjugate Vaccine, Prevnar 13®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
19 Years to 49 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Metairie, Louisiana • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 22, 2026, 5:11 AM EDT
Recruiting Phase 2 Interventional

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

NCT05183854
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Recruiting Phase 3 Interventional

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

NCT07247188
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
PCV21, 20vPCV
Biological
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Omaha, Nebraska • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Recruiting Phase 4 Interventional

Vaccine Responses in Patients With B Cell Malignancies

NCT05170399
View directory record Official record
Conditions
Lymphoma
Interventions
AREXVY, ABRYSVO, PREVNAR 20, PNEUMOVAX 23, Heplisav -B, PREVNAR 13, Shingrix
Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2036
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

NCT00422292
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
87
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

NCT03313037
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13, PPSV23, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
14
States / cities
Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 22, 2026, 5:11 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Vaccine Immunity and Inflammation in the Aging Person Living With HIV

NCT06514547
View directory record Official record
Conditions
HIV Infections, Age
Interventions
Conjugate Pneumococcal Vaccine 20 (PCV20)
Biological
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 22, 2026, 5:11 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

NCT07794748
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
4,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
37
States / cities
Birmingham, Alabama • Lake Forest, California • Walnut Creek, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

NCT03550313
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
48
States / cities
Mobile, Alabama • Harrisburg, Arkansas • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Results available

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

NCT04080531
View directory record Official record
Conditions
Plasma Cell Neoplasm
Interventions
Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 22, 2026, 5:11 AM EDT
Completed No phase listed Observational Results available

Effect of Prevnar 13 on Ear Infections in Children

NCT01199016
View directory record Official record
Conditions
Otitis Media
Interventions
Tympanocentesis, Nose/throat swab, Observational
Procedure · Biological
Lead sponsor
Pfizer
Industry
Eligibility
6 Months to 30 Months
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
7
States / cities
Penfield, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

PPV: Pneumococcal Polysaccharide Vaccine in Older Adults

NCT00239694
View directory record Official record
Conditions
Aging
Interventions
Pneumococcal Vaccine, Meningococcal Vaccine
Biological
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 22, 2026, 5:11 AM EDT